• Username (E-mail)
  • Password
Dow 20,822 0.1%  EStoxx50 3,304 -0.9%  Nikkei 19,284 -0.5%  EUR 1.0566 0.0% 
Nasdaq 5,845 0.2%  FTSE100 7,244 -0.4%  Yen 112.1450 0.0%  Oil 56.0 -0.8% 
S&P500 2,367 0.2%  DAX 11,804 -1.2%  GBP 1.2480 0.2%  Gold 1,257 0.0% 

Vertex Pharmaceuticals share [Symbol: VRTX / ISIN: US92532F1003]

11/20/2015 03:36:17 AM
11/20/2015 03:36:17 AM UTC-0500

Vertex Receives EU Approval For ORKAMBI - Quick Facts


(RTTNews) - Vertex Pharmaceuticals Inc (VRTX) announced the European Commission has granted Marketing Authorization for ORKAMBI (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older who have two copies of the F508del mutation. The company said the approval is based on previously announced data from two 24-week global Phase 3 studies, TRAFFIC and TRANSPORT, and additional interim 24-week data from the subsequent extension study, PROGRESS, in people ages 12 and older who have two copies of the F508del mutation.

"The EU approval of lumacaftor in combination with ivacaftor is a major milestone in our longstanding efforts to develop new medicines that treat the underlying cause of the disease for people with cystic fibrosis," said Jeffrey Leiden, Vertex's CEO.

Analyst Opinions for Vertex Pharmaceuticals Inc.

More Analyst Opinions
  • All
  • Buy
  • Hold
  • Sell
12/14/12
Vertex Pharmaceuticals Goldman Sachs Group Inc.
12/05/12
Vertex Pharmaceuticals RBC Capital Markets
11/13/12
Vertex Pharmaceuticals Credit Suisse Group
11/05/12
Vertex Pharmaceuticals Goldman Sachs Group Inc.
11/02/12
Vertex Pharmaceuticals UBS AG

Add or Edit Instrument

Related Stocks

Stock Market

News Ticker

News

  • News on Stocks
  • All News
pagehit